The high expression of MAGEA associated with progression could be relevant for treatment selection, since increased expression of a subcluster of MAGE-A cancer-germline antigens has been shown to predict resistance specific to CTLA-4, but not PD-1, blockade, and its association with autophagy suppression implicates the role of autophagy in regulating primary resistance to anti-CTLA-4 therapy. The gene discussed is CTLA4; the disease is cancer.